Products
Rivipansel is currently in clinical development at GlycoMimetics and Pfizer. The drug is not yet commercially available.
Structure and properties
Rivipansel (C58H74N6O31S3, Mr = 1447.4 g/mol) is a glycomimetic developed by the research group led by Prof. Beat Ernst at the Institute of Molecular Pharmacy, University of Basel, in collaboration with GlycoMimetics.
Effects
Rivipansel is a pan-selectin antagonist that antagonizes all three selectins (E-selectin, L-selectin, and P-selectin). The selectins are glycoproteins that mediate adhesion of blood cells to the endothelium.
Indications
For the treatment of vaso-occlusive crises (VOC) in sickle cell disease.
